Press Releases

Date	Title	Company
03-Aug-2022	$964 Billion Worldwide Biotechnology Industry to 2027 - Featuring Amgen, Biogen, Novartis and Pfizer Among Others - ResearchAndMarkets.com	Businesswire
03-Aug-2022	Breast Pumps Market valuation of US$ 2.45 Bn by the end of 2030, up from US$ 1.72 Bn in 2022.	MARKITWIRED
03-Aug-2022	Acetaminophen Market is expected to reach US$ 14.07 Billion by 2031	MARKITWIRED
03-Aug-2022	First Aid Market size is expected to be US$ 800.38 Million by 2032	MARKITWIRED
03-Aug-2022	Vaginitis Treatment Drugs Market is expected to progress at 5.2% CAGR to reach US$ 4.52 Bn by the end of 2030	MARKITWIRED
03-Aug-2022	Smart Pill Boxes & Bottles Market to grow at a healthy CAGR of 9.9% between 2022 and 2028	MARKITWIRED
03-Aug-2022	Real-time Bioprocess Raman Analyzer Market	MARKITWIRED
03-Aug-2022	Invitation: Straumann Group 2022 half-year financial results webcast	Straumann Holding AG
03-Aug-2022	Becoming a cannabis ecosystem: SynBiotic SE management update	SynBiotic SE
03-Aug-2022	External Fixators Market Future Demands, Regional Developments and Industry Competitive Landscape Analysis 2028	MARKITWIRED
03-Aug-2022	Diabetic Macular Edema Market Analysis, Size, Share, Opportunities and Forecast To 2027 \|Future Market Insights	MARKITWIRED
03-Aug-2022	The Global Cell Culture Media Bags Market is Projected to Reach US$ 2.67 by the end of 2030\| Cell Culture Media Bags Size, Share, Trends and Analysis	MARKITWIRED
03-Aug-2022	Veterinary Imaging Market Forecast 2030 \| Size, Share, Growth & Forecast \|Future Market Insights	MARKITWIRED
03-Aug-2022	PD1/PDL1 Inhibitors Market Analysis by Type, Application, Growth, Demand, Status, and Forecast 2030	MARKITWIRED
03-Aug-2022	TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial	Businesswire
03-Aug-2022	U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®**	Polpharma Biologics
03-Aug-2022	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer	Businesswire
03-Aug-2022	U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2	Formycon AG
03-Aug-2022	Antibiotic Research UK Announces New CEO	Sciad Newswire
03-Aug-2022	Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2	Formycon AG